Ipsen’s general manager for Middle East and Africa (MEA), Khaled Elrefae, highlights the French firm’s expanding footprint in the region, the fundamentals that make MEA a growth driver for Ipsen, and the opportunities for further growth from its oncology, rare disease and neuroscience portfolios. In addition, Elrefae discusses the changing dynamics in the Saudi market, including improvements to the registration and procurement systems.
Saudi Arabia is one of the fastest growing markets within the MEA region. The Saudi government is taking bold decisions to transform the healthcare system and providing pharmaceutical companies with fantastic opportunities to join this transformational journey
